• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis
【2h】

Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis

机译：阿德福韦酯对慢性乙型肝炎和肝硬化患者T细胞免疫功能的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of the present study was to investigate the T cell immune function in chronic hepatitis B hepatocirrhosis patients at the compensated and decompensated stage following treatment with adefovir dipivoxil. A total of 104 patients diagnosed with hepatitis B hepatocirrhosis during the period from October 2013 to October 2014 were enrolled in the study. Among the cases, there were 56 cases at compensated stage, and another 48 at decompensated stage. Adefovir dipivoxil was administered for antiviral therapy (10 mg/time, 1 time/day, for a total of 24 weeks), and we compared the virus disappearance rate, liver function improvement and T cell immune function between the two groups before and after treatment. The difference between the virus disappearance rate in the two groups was not statistically significant (P>0.05). The decreased level of ALT decrease in the compensated group was significantly higher than that in the decompensated group, while the increased level of albumin in the compensated group was significantly higher as well. The differences showed statistical significance (P<0.05). After treatment, the level of CD4+ and CD4+/CD8+ ratio were higher than before treatment, while the level of CD8+ was lower after treatment than before treatment in the two groups. The differences all showed statistical significance (P<0.05). The CD4+CXCR5+ T follicular helper (TFH) cell level in the two groups was higher after treatment, as was interleukin-2 and interferon-γ. The differences all showed statistical significance (P<0.05). As for comparison between groups, the difference had no statistical significance (P>0.05). Adefovir dipivoxil treatment can improve T cell immune function at the compensated and decompensated stages in chronic hepatitis B hepatocirrhosis patients. This may be associated with virus disappearance and liver function improvement.
机译：本研究的目的是研究在用阿德福韦酯治疗后的代偿期和代偿期的慢性乙型肝炎肝硬化患者的T细胞免疫功能。 2013年10月至2014年10月期间，共104例被诊断出患有乙型肝炎肝硬化的患者入选了该研究。在这些案件中，赔偿期有56宗，补偿期则有48宗。阿德福韦酯（Defivoxil）用于抗病毒治疗（10 mg /次，1次/天，共24周），我们比较了两组治疗前后的病毒消失率，肝功能改善和T细胞免疫功能。两组病毒消失率差异无统计学意义（P> 0.05）。补偿组的ALT降低水平明显低于失代偿组，而补偿组白蛋白升高水平也明显更高。差异具有统计学意义（P <0.05）。治疗后，CD4 + 和CD4 + / CD8 + 比值均高于治疗前，而CD8 两组治疗后+ 均低于治疗前。差异均具有统计学意义（P <0.05）。两组治疗后CD4 + CXCR5 + T卵泡辅助细胞（TFH）水平较高，白细胞介素2和干扰素-γ也较高。差异均具有统计学意义（P <0.05）。两组间比较差异无统计学意义（P> 0.05）。阿德福韦酯在慢性乙型肝炎肝硬化患者的补偿和失代偿期可改善T细胞免疫功能。这可能与病毒消失和肝功能改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号